TY - JOUR
T1 - Crosstalk between angiogenesis and immune regulation in the tumor microenvironment
AU - Kim, Hei Jung
AU - Ji, Young Rae
AU - Lee, You Mie
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/6
Y1 - 2022/6
N2 - Cancer creates a complex tumor microenvironment (TME) composed of immune cells, stromal cells, blood vessels, and various other cellular and extracellular elements. It is essential for the development of anti-cancer combination therapies to understand and overcome this high heterogeneity and complexity as well as the dynamic interactions between them within the TME. Recent treatment strategies incorporating immune-checkpoint inhibitors and anti-angiogenic agents have brought many changes and advances in clinical cancer treatment. However, there are still challenges for immune suppressive tumors, which are characterized by a lack of T cell infiltration and treatment resistance. In this review, we will investigate the crosstalk between immunity and angiogenesis in the TME. In addition, we will look at strategies designed to enhance anti-cancer immunity, to convert “immune suppressive tumors” into “immune activating tumors,” and the mechanisms by which these strategies enhance effector immune cell infiltration.
AB - Cancer creates a complex tumor microenvironment (TME) composed of immune cells, stromal cells, blood vessels, and various other cellular and extracellular elements. It is essential for the development of anti-cancer combination therapies to understand and overcome this high heterogeneity and complexity as well as the dynamic interactions between them within the TME. Recent treatment strategies incorporating immune-checkpoint inhibitors and anti-angiogenic agents have brought many changes and advances in clinical cancer treatment. However, there are still challenges for immune suppressive tumors, which are characterized by a lack of T cell infiltration and treatment resistance. In this review, we will investigate the crosstalk between immunity and angiogenesis in the TME. In addition, we will look at strategies designed to enhance anti-cancer immunity, to convert “immune suppressive tumors” into “immune activating tumors,” and the mechanisms by which these strategies enhance effector immune cell infiltration.
KW - Angiogenesis
KW - Immune suppressive tumor
KW - Treg cells
KW - Tumor microenvironment
KW - Tumor-associated macrophage
UR - http://www.scopus.com/inward/record.url?scp=85132880431&partnerID=8YFLogxK
U2 - 10.1007/s12272-022-01389-z
DO - 10.1007/s12272-022-01389-z
M3 - Review article
C2 - 35759090
AN - SCOPUS:85132880431
SN - 0253-6269
VL - 45
SP - 401
EP - 416
JO - Archives of Pharmacal Research
JF - Archives of Pharmacal Research
IS - 6
ER -
